Drug Profile
Viagenpumatucel-L - NightHawk Biosciences/University of Miami
Alternative Names: Ad100-gp96Ig-HLA A1; Gp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell line; gp96-Ig lung cancer vaccine - NightHawk Biosciences /University of Miami; HS-110; HS-L1Latest Information Update: 08 Apr 2023
Price :
$50
*
At a glance
- Originator University of Miami
- Developer NightHawk Biosciences
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Heat-shock protein stimulants; Immunostimulants; OX40 ligand stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours
Most Recent Events
- 31 Mar 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, In adults) in USA (Intradermal) (before March 2023)
- 31 Mar 2023 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (before March 2023)
- 01 Jan 2023 NightHawk Biosciences terminates its licensing agreement with University of Miami for gp96 and TNFRSF25 platforms